Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant, dose-dependent weight loss in adults with obesity, with tirzepatide demonstrating the highest efficacy.
If you have obesity, GLP-1 medications like semaglutide or tirzepatide are highly effective tools for weight loss, often outperforming lifestyle changes alone. The key to success is starting at the lowest dose and titrating up slowly to minimize gastrointestinal side effects, which usually subside over time. Consult a healthcare provider to determine if you are a candidate based on your BMI and health history.
In clinical trials, liraglutide showed a placebo-corrected weight loss of around 5 %, semaglutide 12 %, and tirzepatide 18 %.
Why this rating
Based on multiple large-scale RCTs (SCALE, STEP, SURMOUNT-1) and meta-analyses cited in the review.
Source
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks
Wissam Ghusn et al. · Obesity Pillars · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →